{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:15:24Z","timestamp":1792656924531,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) di\ufb00erences in the outcomes according to the biological treatment line: biologic-na\u00efve patients (<jats:italic>group A<\/jats:italic>) versus multifailure (<jats:italic>group B<\/jats:italic>) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous\/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity\/functional\/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p&lt;0.01). At T24, <jats:italic>group A<\/jats:italic> showed lower Psoriasis Area Severity Index (p=0.04), erythrocyte sedimentation rate and C reactive protein (p=0.03 ;p=0.05) and joint count (p=0.03) compared with <jats:italic>group B<\/jats:italic>. At T24, MDA was achieved in 75.71% of <jats:italic>group A<\/jats:italic> and 70.37% of <jats:italic>group B<\/jats:italic>. Treatment was discontinued in 123 (20.23%) patients, mainly due to primary\/secondary loss of effectiveness, and in 22 due to adverse events. Retention rate at T24 was 71% in the whole population, with some difference depending on secukinumab dosage (p=0.004) and gender (p=0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001519","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T19:12:31Z","timestamp":1613502751000},"page":"e001519","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padova, Padova, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Lorenzin","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padova, Padova, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3112-6488","authenticated-orcid":false,"given":"Antonio","family":"Carriero","sequence":"additional","affiliation":[{"name":"Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza Local Health System, Potenza, Basilicata, Italy"},{"name":"Department of Medicine and Health Sciences, University of Molise, Campobasso, Molise, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of \"Medicina dei Sistemi\", University of Rome Tor Vergata, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-6607","authenticated-orcid":false,"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University of Naples Federico II, Napoli, Campania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Rheumatology, ASST Gaetano Pini-CTO, Milano, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[{"name":"Academic Rheumatology Unit, Dipartimento di Medicina e Scienze per la Salute \"Vincenzo Tiberio\", University of Molise, Campobasso, Molise, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Internal Medicine, Azienda USL-IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy"},{"name":"University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, AOU and University of Cagliari, Cagliari, Sardegna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Semeraro","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Martina Franca-ASL Taranto, Martina Franca Hospital, Martina Franca, Puglia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Santo","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Azienda Sanitaria Locale Barletta Andria Trani\u2014DSS4 Barletta, Andria, Puglia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padova, Padova, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-4983","authenticated-orcid":false,"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padova, Padova, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Virelli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Masia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Martina Franca-ASL Taranto, Martina Franca Hospital, Martina Franca, Puglia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Visalli","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, A.O.U. Policlinico S. Marco, University of Catania, Catania, Sicilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Amato","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, A.O.U. Policlinico S. Marco, University of Catania, Catania, Sicilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, A.O.U. Policlinico S. Marco, University of Catania, Catania, Sicilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2025090312473432000_7.1.e001519.1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312473432000_7.1.e001519.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.001"},{"key":"2025090312473432000_7.1.e001519.3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"2025090312473432000_7.1.e001519.4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312473432000_7.1.e001519.5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312473432000_7.1.e001519.6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00296-013-2876-z","article-title":"High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study","volume":"34","author":"Henes","year":"2014","journal-title":"Rheumatol Int"},{"key":"2025090312473432000_7.1.e001519.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2025090312473432000_7.1.e001519.8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723"},{"key":"2025090312473432000_7.1.e001519.9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40265-016-0557-4","article-title":"Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis","volume":"76","author":"Lubrano","year":"2016","journal-title":"Drugs"},{"key":"2025090312473432000_7.1.e001519.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2025090312473432000_7.1.e001519.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090312473432000_7.1.e001519.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025090312473432000_7.1.e001519.13","doi-asserted-by":"publisher","DOI":"10.1186\/ar4317"},{"key":"2025090312473432000_7.1.e001519.14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0426-z"},{"key":"2025090312473432000_7.1.e001519.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2025090312473432000_7.1.e001519.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090312473432000_7.1.e001519.17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312473432000_7.1.e001519.18","first-page":"991","article-title":"Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of rheumatology","volume":"35","author":"Marchesoni","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312473432000_7.1.e001519.19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.16124","article-title":"Long\u2010term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease","volume":"34","author":"Reich","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312473432000_7.1.e001519.20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00872","article-title":"Mini review: new treatments in psoriatic arthritis. focus on the IL-23\/17 axis","volume":"10","author":"Sakkas","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025090312473432000_7.1.e001519.21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090312473432000_7.1.e001519.22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr2.11097","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 future 1 study","volume":"2","author":"Mease","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025090312473432000_7.1.e001519.23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090312473432000_7.1.e001519.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"2025090312473432000_7.1.e001519.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"2025090312473432000_7.1.e001519.26","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312473432000_7.1.e001519.27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1759720X18787766","article-title":"The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis","volume":"10","author":"Garcia-Montoya","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090312473432000_7.1.e001519.28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40261-019-00856-8","article-title":"Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab","volume":"39","author":"Magrey","year":"2019","journal-title":"Clin Drug Investig"},{"key":"2025090312473432000_7.1.e001519.29","first-page":"30112","article-title":"Secukinumab as biological treatment for psoriatic arthritis in real clinical practice","author":"Pinto Tasende","year":"2019","journal-title":"Reumatol Clin"},{"key":"2025090312473432000_7.1.e001519.30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fmed.2020.00288","article-title":"Real life efficacy and safety of Secukinumab in Biologic-Experienced patients with psoriatic arthritis","volume":"7","author":"Klavdianou","year":"2020","journal-title":"Front Med"},{"key":"2025090312473432000_7.1.e001519.31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14712598.2020.1761957","article-title":"One-Year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study","volume":"20","author":"Chimenti","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025090312473432000_7.1.e001519.32","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"2025090312473432000_7.1.e001519.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.5566"},{"key":"2025090312473432000_7.1.e001519.34","doi-asserted-by":"crossref","unstructured":"Michelsen B , \u00d8rnbjerg LM , Kvien TK . Impact of discordance between patient\u2019s and evaluator\u2019s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology 2020:kez656.","DOI":"10.1093\/rheumatology\/kez656"},{"key":"2025090312473432000_7.1.e001519.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025090312473432000_7.1.e001519.36","first-page":"S64","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle Enthesitis index (Mei), Leeds Enthesitis index (LEI), spondyloarthritis research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis Enthesis score (MASES), Leeds Dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness Therapy-Fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025090312473432000_7.1.e001519.37","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2025090312473432000_7.1.e001519.38","unstructured":"Secukinumab . Summary of product characteristics. Available: from:http:\/\/www.ema.europa.eu\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac058001d124cited [Accessed 25 Apr 2019]."},{"key":"2025090312473432000_7.1.e001519.39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10067-017-3953-6","article-title":"Effectiveness and safety of ustekinumab in na\u00efve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study","volume":"37","author":"Chimenti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090312473432000_7.1.e001519.40","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"2025090312473432000_7.1.e001519.41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312473432000_7.1.e001519.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090312473432000_7.1.e001519.43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090312473432000_7.1.e001519.44","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/jdv.14391","article-title":"Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the clear study","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312473432000_7.1.e001519.45","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"2025090312473432000_7.1.e001519.46","doi-asserted-by":"crossref","unstructured":"Reich K , Sullivan J , Arenberger P . Secukinumab shows high and sustained effectiveness in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol 2020.","DOI":"10.1111\/bjd.19262"},{"key":"2025090312473432000_7.1.e001519.47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2025090312473432000_7.1.e001519.48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2019.02.062","article-title":"A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients","volume":"81","author":"Ortiz-Salvador","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090312473432000_7.1.e001519.49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090312473432000_7.1.e001519.50","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.638","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 maximise trial","author":"Baraliakos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090312473432000_7.1.e001519.51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025090312473432000_7.1.e001519.52","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190507"},{"key":"2025090312473432000_7.1.e001519.53","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015599446"},{"key":"2025090312473432000_7.1.e001519.54","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025090312473432000_7.1.e001519.55","first-page":"342","article-title":"Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry","volume":"37","author":"Mann","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312473432000_7.1.e001519.56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket433"},{"key":"2025090312473432000_7.1.e001519.57","first-page":"107","article-title":"An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab","volume":"38","author":"Scrivo","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312473432000_7.1.e001519.58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study","volume":"81","author":"Torres","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090312473432000_7.1.e001519.59","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01497","article-title":"Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study","volume":"10","author":"D'Angelo","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025090312473432000_7.1.e001519.60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: updated results from Slovenian national Registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int J Dermatol"},{"key":"2025090312473432000_7.1.e001519.61","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s10067-019-04663-6","article-title":"Psoriatic arthritis and obesity: the role of anti-IL-12\/IL-23 treatment","volume":"38","author":"Costa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090312473432000_7.1.e001519.62","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8595-z"},{"key":"2025090312473432000_7.1.e001519.63","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.semarthrit.2020.01.012","article-title":"Remission in psoriatic arthritis: definition and predictors","volume":"50","author":"Alharbi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312473432000_7.1.e001519.64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:47:46Z","timestamp":1756928866000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/rmdopen-2020-001519"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001519","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}